deltatrials
Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00630565

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Leukemia
Interventions bone marrow transplantation busulfan cyclophosphamide dexamethasone etoposide hematopoietic stem cell transplantation peripheral blood stem cell transplantation sargramostim total-body irradiation
Updated 14 times since 2017 Last updated: Jan 9, 2024 Started: Jul 26, 2006 Primary completion: Jul 28, 2022 Completion: Jul 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow Accrual

Other terminated trials from Masonic Cancer Center, University of Minnesota

See all terminations from Masonic Cancer Center, University of Minnesota

Other Leukemia trials with similar outcome

Browse all Leukemia trials

A PHASE2/PHASE3 clinical study on Leukemia, this trial is terminated or withdrawn. The trial is conducted by Masonic Cancer Center, University of Minnesota and has accumulated 14 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Oct 2019 · 12 months · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2022 · 15 months · monthly snapshot~May 2022 – ~Jan 2023 · 8 months · monthly snapshot~Jan 2023 – ~Feb 2024 · 13 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE2_PHASE3

  4. Jan 2023 — Feb 2024 [monthly]

    Terminated PHASE2_PHASE3

    Status: Completed → Terminated

  5. May 2022 — Jan 2023 [monthly]

    Completed PHASE2_PHASE3

    Status: Recruiting → Completed

▶ Show 9 earlier versions

  1. Feb 2021 — May 2022 [monthly]

    Recruiting PHASE2_PHASE3

  2. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2_PHASE3

  3. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  4. Oct 2019 — Feb 2020 [monthly]

    Recruiting PHASE2_PHASE3

  5. Oct 2018 — Oct 2019 [monthly]

    Recruiting PHASE2_PHASE3

  6. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2_PHASE3

  7. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  8. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2_PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Masonic Cancer Center, University of Minnesota
Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations